Palovarotene is under clinical development by Ipsen and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Palovarotene’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Palovarotene (Sohonos) is a member of the retinoid class of drugs that is associated with birth defects in humans. It is formulated as capsules for oral administration. Sohonos is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with Fibrodysplasia (myositis) Ossificans Progressiva.
Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatic diseases. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.
For a complete picture of Palovarotene’s drug-specific PTSR and LoA scores, buy the report here.